Psychedelics work, in part, by creating a window, or a period of heightened neuroplasticity during which the brain is unusually receptive to new patterns of meaning, connection, and self-understanding. Research by Gül Dölen and colleagues suggests that psychedelics may temporarily reopen critical-period plasticity, particularly in social reward learning, creating a neurobiological opening that resembles developmental states of maximum learning. This window is real, but it is also temporary.
The question that follows is not whether the window opens. The evidence that it does is now substantial. The question is what happens inside that window.
Most clinical protocols have focused their attention on the medicine session itself — on dose, setting, music, and therapist presence — and on integration support after the fact. Mindfulness, when it appears at all, tends to appear in the preparation phase as a tool for managing anxiety, or in integration as a journaling adjunct. It is treated as a support practice, the scaffolding around the main substance-dependent event.
This framing misses something important. The neural mechanisms through which mindfulness operates and the neural mechanisms through which psychedelics operate overlap — substantially, and in ways that are not coincidental. Understanding that overlap reframes the question from whether mindfulness is helpful to whether psychedelic-assisted therapy, conducted without it, is operating at its full potential.
What the Brain Does Under Both
The Default Mode Network is a cluster of brain regions associated with self-referential thinking, autobiographical memory, and the kind of ruminative, narrative self-processing that underlies many forms of psychological suffering, including addiction, anxiety, and depression. In depression, the DMN is overactive — the self-story loops, the past intrudes, the future becomes a projection of the worst of what’s already happened. Much of what feels like being stuck is, at the neurological level, a DMN that cannot release its grip.
Both mindfulness meditation and psychedelics disrupt this. Brewer and colleagues demonstrated in 2011 that experienced meditators show significantly reduced DMN activity and altered connectivity patterns compared to non-meditators — the narrative self-center quiets, and attention becomes available for the present moment. Psychedelics produce a comparable disruption through a different route: by activating 5-HT2A receptors concentrated in association cortex within the DMN, they temporarily loosen the hierarchical control through which the brain’s top-down predictions ordinarily filter experience.
Carhart-Harris and Friston formalised this as the REBUS model: Relaxed Beliefs Under Psychedelics. Under normal conditions, the brain is a prediction machine as it interprets incoming sensory information through the lens of its established priors, its beliefs about what the world is and what the self is within it. These priors are efficient. They are also, in certain psychological conditions, the problem. Rigid priors sustain rigid suffering. The REBUS model proposes that psychedelics temporarily flatten the hierarchy — prior-weighted top-down processing relaxes, bottom-up sensory and emotional information rises, and the system becomes, briefly, more open to revision.
What is often underemphasised is that this openness is not, in itself, therapeutic. A loosened prior is not a corrected one. The plasticity window is a condition of possibility, not an outcome. For reorganisation to resolve adaptively — for the loosened system to reconsolidate around healthier patterns — something needs to direct that reorganisation. This is where the convergence becomes clinically significant.
Mindfulness training does not simply quiet the DMN in the abstract. It builds a specific set of attentional capacities: present-moment orientation, non-reactive observation of mental events, acceptance of difficult emotional material without avoidance or identification. These are precisely the capacities that determine what happens when the psychedelic window opens. A person who has cultivated the ability to observe distressing thoughts without being overtaken by them is differently positioned inside a psychedelic experience than one who has not. The window opens either way. What comes through it depends on what the person can hold.
The Decentering Bridge
Both mindfulness and psychedelics produce a shift that researchers call decentering, which is the capacity to observe thoughts and emotions as transient mental events rather than as literal truth or stable identity. In mindfulness-based approaches, decentering is understood as one of the primary mechanisms of therapeutic action: it breaks the fusion between self and thought that sustains depression, anxiety, and rumination. In psychedelic experiences, something functionally similar occurs through ego-dissolution — the softening or temporary collapse of the ordinary sense of a bounded, continuous self.
These are not identical processes. Ego-dissolution during a psychedelic session is often abrupt, non-volitional, and of an intensity that exceeds anything produced by standard mindfulness training. But they share a structural logic: both create conditions in which the identification of self with thought loosens, and experience becomes available in a more immediate, less narrative-filtered form.
The therapeutic implication of this convergence is under-appreciated. Research by Eleftheriou and Thomas found that individuals with prior mindfulness experience report more profound and enduring benefits from psychedelic-assisted therapy — not simply because they are calmer going in, but because the decentering capacities they have cultivated give them a relational framework for the states they encounter. They have practised not-identifying. When ego-dissolution arrives, they have more psychological room to meet it.
Conversely, psychedelics appear to enhance trait mindfulness even in people without prior meditation practice — the experience itself shifts something in the ongoing relationship between self and thought. What this suggests is not that psychedelics replace mindfulness training, but that the two practices are mutually amplifying. They work the same mechanism from different angles. The question for clinical design is whether it makes sense to deploy only one.
Preparation Is Not Anxiety Management
Current PAT protocols often include some form of preparatory mindfulness as a practical measure — body scan practices to reduce pre-session anxiety, breathing techniques to support grounding. This is legitimate and useful. It is also a limited reading of what preparation can do.
The preparation phase, understood through the lens of neurological convergence, is not primarily about reducing anxiety. It is about cultivating the attentional capacities that will determine what happens in the session itself. The window does not open into a vacuum. It opens into the person’s existing patterns of attention, their habitual orientation toward difficult experience, their capacity to stay present when ordinary defences relax.
Structured mindfulness training in the weeks before a psychedelic session is not preparation in the colloquial sense of getting ready. It is practice for the specific cognitive conditions the session will produce. The breath-return — the basic gesture of noticing the mind has wandered and returning attention to the present — is not only a meditation technique. It is training for the capacity to stay oriented during disorientation. Present-moment awareness built through sitting practice translates directly into the session: the person who has cultivated it can turn toward difficult material that arises, rather than away from it.
Jon Kabat-Zinn defined mindfulness as awareness arising through purposeful, non-judgmental, present-moment attention — a definition that has generated decades of clinical application. What that definition points at is a skill, not a disposition. Skills are built through practice. The argument for integrating substantive mindfulness training into PAT preparation is not philosophical; it is practical.
Navigation: Anchor in the Storm
The navigation phase — the session itself — is where the theoretical case becomes most concrete. Psychedelic experiences can move quickly and intensely across a wide range of emotional and perceptual territory. What the research consistently identifies as most determinative of outcomes is not the peak content of the experience but how the person relates to what arises — whether they can move toward difficult material or are moved away from it.
Mindfulness-based navigation draws on practices that become genuinely useful here: sensory anchoring through breath or body awareness, non-reactive observation of mental phenomena, and the acceptance-based orientation that allows difficult emotions to be present without triggering avoidance or identification. These are not simply comfort measures. They are functional capacities that alter what the session can therapeutically accomplish.
A person trained in mindfulness has, in effect, been rehearsing the fundamental cognitive stance that makes a challenging psychedelic session therapeutically generative rather than merely intense. The ability to witness rather than fuse, to stay with rather than flee — these capacities do not arrive automatically when the medicine opens the system. They are available to those who have built them.
This matters practically for therapists and guides. A participant without mindfulness training who encounters difficult material in a session is more likely to require active management of the experience, such as redirection, reassurance, and containment. A participant with training has more internal resources available. The presence of a well-trained therapist remains essential regardless; the question is what the therapeutic dyad is working with.
Integration: Closing the Window Wisely
The REBUS model’s most important implication for integration has not yet been fully absorbed by the field. If psychedelics work by temporarily relaxing predictive priors, then what happens in the period after the session — when the system is settling back toward its habitual patterns — is not aftermath. It is the moment when reconsolidation occurs. The priors that were loosened during the session will restabilise. The question is whether they restabilise around the same patterns or different ones.
Mindfulness practice in integration is often framed as a way to process the experience — journaling, reflection, meaning-making. These are not trivial. But the deeper function of sustained mindfulness practice in the post-session period is neurological: it provides a repeated, structured orientation toward the new patterns of attention and self-relationship that the experience made briefly available. Every meditation sitting in the weeks after a session is a practice of returning to — and thereby reinforcing — the more open, less rigidly self-referential mode of cognition that the psychedelic temporarily revealed.
This is why integration cannot be treated as a passive period of reflection. The window that opened during the session does not close instantly; there is a period of heightened plasticity and sensitivity that extends into the days and weeks following. Systematic mindfulness practice during this period is not maintenance. It is cultivation. It determines, in part, what consolidates.
The critique of commercialised mindfulness is instructive here. Elf, Isham, and Leoni have documented how mindfulness underwent a process of decontextualisation from its original Buddhist ethical framework — stripped of its relational and communal roots, it became a tool for individual stress management that could be deployed in any context, including contexts directly opposed to its foundational values. The U.S. Army’s adoption of mindfulness is only the sharpest example of what happens when a practice is separated from the understanding of human wellbeing that gave it meaning.
The same risk is visible in the emerging psychedelic field. Clinical framing prioritises the measurable, the scalable, and the individually applicable. Mindfulness enters as a module, psychedelics enter as a medicine, and the relational and contemplative traditions from which both emerged are bracketed as non-essential. What is at stake in that bracketing is not merely cultural sensitivity. It is therapeutic and transformative efficacy.
The Argument in Plain Terms
Mindfulness and psychedelic-assisted therapy share the same primary neurological mechanism — DMN disruption and the relaxation of habitual self-referential processing. They produce convergent phenomenological states — decentering, ego-softening, present-moment immediacy. They reinforce each other’s effects: prior mindfulness training deepens psychedelic outcomes; psychedelic experiences deepen trait mindfulness. And the critical-period plasticity that psychedelics open requires directed practice to consolidate into lasting change.
The case for treating mindfulness as structurally integral to PAT — not optional, not supplementary, not a module — follows from these convergences. It is not primarily a values argument about honouring contemplative traditions, though that argument also stands. It is a mechanistic argument: these practices are working the same pathway. Deploying only one of them when both are available, and when their combination is documented to produce superior outcomes, requires justification.
The field is at a moment of design. Clinical protocols are being standardised, training programmes are forming, regulatory frameworks are being built. The decisions being made now about what belongs inside a psychedelic therapy protocol and what is optional will shape what psychedelic-assisted therapy becomes. Treating mindfulness as core rather than adjunct is one of those decisions.
The window opens either way. The question is whether we are ready for what comes through it.
Toward Psychedelic-Assisted Mindfulness Therapy (PAMT)
The convergences described here — neurological, phenomenological, clinical — point toward something more than a set of complementary practices. They point toward a unified therapeutic framework, one in which mindfulness meditation is not integrated into psychedelic-assisted therapy as an adjunct but is constitutive of it from the start.
At Psygaia, we are calling this Psychedelic-Assisted Mindfulness Therapy, or PAMT. Not a protocol yet — the research needed to formalise one is still ahead. But a direction. A recognition that the window psychedelics open and the attentional capacities mindfulness builds are not two separate therapeutic bets. They are two expressions of the same underlying process, and designing them apart from each other is leaving something on the table.
What that framework looks like in practice — how mindfulness training is sequenced, how depth of practice interacts with session outcomes, how integration is structured across the weeks following — are open questions worth pursuing. PAMT names the territory, and the work of mapping it is only beginning.
Sources
Belleau, L. (2025). The Psygaia Framework: Integration as Reconnection.
Brewer, J. A., Worhunsky, P. D., Gray, J. R., Tang, Y.-Y., Weber, J., & Kober, H. (2011). Meditation experience is associated with differences in default mode network activity and connectivity. Proceedings of the National Academy of Sciences, 108(50), 20254–20259. https://doi.org/10.1073/pnas.1112029108
Carhart-Harris, R. L., & Friston, K. J. (2019). REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacological Reviews, 71(3), 316–344. https://doi.org/10.1124/pr.118.017160
Chambers, R., Stoliker, D., & Simonsson, O. (2023). Psychedelic-assisted psychotherapy and mindfulness-based cognitive therapy: Potential synergies. Mindfulness, 14, 2111–2123. https://doi.org/10.1007/s12671-023-02206-4
Dahl, C. J., Lutz, A., & Davidson, R. J. (2015). Reconstructing and deconstructing the self: Cognitive mechanisms in meditation practice. Trends in Cognitive Sciences, 19(9), 515–523. https://doi.org/10.1016/j.tics.2015.07.001
Eleftheriou, M. E., & Thomas, E. (2021). Examining the potential synergistic effects between mindfulness training and psychedelic-assisted therapy. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.707057
Elf, M., Isham, A., & Leoni, M. (2023). Critiques of commercialised mindfulness and the future of commercialised psychedelics.
Heuschkel, K., & Kuypers, K. P. C. (2020). Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.00224
Holas, P., & Kamińska, J. (2023). Mindfulness meditation and psychedelics: Potential synergies and commonalities. Pharmacological Reports, 75(6), 1398–1409. https://doi.org/10.1007/s43440-023-00551-8
Kabat-Zinn, J. (1982). An outpatient program in behavioral medicine for chronic pain patients based on the practice of mindfulness meditation: Theoretical considerations and preliminary results. General Hospital Psychiatry, 4(1), 33–47. https://doi.org/10.1016/0163-8343(82)90026-3
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
Payne, J. E., Chambers, R., & Liknaitzky, P. (2021). Combining psychedelic and mindfulness interventions: Synergies to inform clinical practice. ACS Pharmacology & Translational Science, 4(2), 416–423. https://doi.org/10.1021/acsptsci.1c00034
